|
[Related PubMed/MEDLINE]
Total Number of Papers: 8
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: rscu-PA |
| Long Form |
: recombinant single-chain u-PA |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
1997 |
The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats. |
LRP, u-PAR, uPA |
| 2 |
1994 |
Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. |
BIA, PAI-1, rtcu-PA, uPA |
| 3 |
1992 |
An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA. |
AA1-263, ELISA, uPA |
| 4 |
1992 |
Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala. |
uPA |
| 5 |
1992 |
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog. |
rt-PA, tPA, uPA |
| 6 |
1991 |
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. |
BsMAb, mAb, tcu-PA, uPA |
| 7 |
1990 |
A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. |
ELISA, rPAI-1, rtcu-PA, uPA |
| 8 |
1989 |
The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. |
Lys-plasminogen, uPA |
|
A Search Service for Abbreviation / Long Form
